Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Boris Ionin"'
Publikováno v:
Pathogens, Vol 9, Iss 5, p 370 (2020)
Bacillus anthracis has been identified as a potential military and bioterror agent as it is relatively simple to produce, with spores that are highly resilient to degradation in the environment and easily dispersed. These characteristics are importan
Externí odkaz:
https://doaj.org/article/d79906fb7cb34d16bd40f575a00cc1a9
Autor:
Boris Ionin, Vladimir Savransky, Sukjoon Park, Michael J. Lacy, Jon R Inglefield, C Steven Godin, Bruna Blauth, Veena V Rao, Joshua J. Reece
Publikováno v:
Int J Toxicol
AV7909 is a next-generation anthrax vaccine under development for post-exposure prophylaxis following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with the recommended antibacterial regimen. AV7909 consists of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43824d8c17ecef1409dd419681abb9e9
https://doi.org/10.1177/10915818211031239
https://doi.org/10.1177/10915818211031239
Autor:
Na Li, Lisa N. Henning, Mario H. Skiadopoulos, Jeffry D. Shearer, Vladimir Savransky, Joshua J. Reece, Daniel C. Sanford, Boris Ionin
Publikováno v:
Vaccine. 39:1-5
The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for post-exposure prophylaxis (PEP) against inhalational anthrax. In clinical studies, two vaccinations with AV7909 administered either two or four weeks apart induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bef73b7e07756217411a45b862dc8c5
https://doi.org/10.1016/j.vaccine.2020.10.095
https://doi.org/10.1016/j.vaccine.2020.10.095
Autor:
Vladimir Savransky, Jeffry D. Shearer, Aaron P. Miles, Cheryl A. Triplett, Daniel C. Sanford, Christian Ruiz, Jee Loon Look, Vladimir G. Frolov, Boris Ionin, Joshua J. Reece, Daniel Callahan, M. Autumn Smiley, Ericka Ruiz
Publikováno v:
Vaccine
The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the anthrax vaccine adsorbed (AVA) (Emergent BioSolutions Inc., Lansing, MI) bul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3048b00e459529393a7b35c1fa83aee3
https://doi.org/10.1016/j.vaccine.2019.09.015
https://doi.org/10.1016/j.vaccine.2019.09.015
Autor:
Jeffry D. Shearer, Bruna Blauth, Jeff D Ballin, Eve Mylchreest, Joshua J. Reece, M. Autumn Smiley, Boris Ionin, Vladimir Savransky
Publikováno v:
Birth Defects Research
The AV7909 vaccine, consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and the immunostimulatory Toll‐like receptor 9 agonist oligodeoxynucleotide adjuvant CPG 7909. The purpose of this research was to evaluate the potential materna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98c1f2df5891f439f40def74e567bacf
https://pubmed.ncbi.nlm.nih.gov/33067910
https://pubmed.ncbi.nlm.nih.gov/33067910
Autor:
Jeffry D. Shearer, Joshua J. Reece, Laurence Lemiale, Vladimir Savransky, Roy E. Barnewall, Boris Ionin, Mario H. Skiadopoulos, Michelle L. Vassar, Mark R. Perry, Sukjoon Park
Publikováno v:
Vaccine
A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax countermeasu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125ed03c4c1cfb0b86dc9e04006f1af4
https://europepmc.org/articles/PMC8905666/
https://europepmc.org/articles/PMC8905666/
Publikováno v:
International journal of toxicology. 38(3)
A recombinant protective antigen (rPA) anthrax vaccine candidate (rPA7909) was developed as a next-generation vaccine indicated for postexposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The lyophilized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0577fbb87a4e76dc82ec095a5f1c2d0d
https://pubmed.ncbi.nlm.nih.gov/31179828
https://pubmed.ncbi.nlm.nih.gov/31179828
Autor:
Daniel C. Sanford, Na Li, Vladimir Savransky, Gloria S. Sivko, Gregory V. Stark, Michael J. Lacy, Mario H. Skiadopoulos, Melicia Gainey, Boris Ionin, Jeffry D. Shearer
Publikováno v:
Vaccine. 35(37)
The anthrax vaccine candidate AV7909 is being developed as a next generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the Anthrax Vaccine Adsorbed (AVA, BioThrax®) bulk drug substance adjuvanted wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82fbde3b1c1d7f8a609032d518806fa9
https://pubmed.ncbi.nlm.nih.gov/28774566
https://pubmed.ncbi.nlm.nih.gov/28774566
Autor:
Ekaterina Vert-Wong, Suha Sari, Thomas L. Rudge, Robert J. Hopkins, Tina Guina, Frances M. Reid, Cris Howard, Gregory V. Stark, Jeffrey G. Smith, Boris Ionin, Gloria S. Sivko, Virginia Johnson, Kristin H. Clement, M. Lisa Swoboda, Gary S. Nabors, Mario H. Skiadopoulos, Brett Pleune, Alison Innes
Publikováno v:
Clinical and Vaccine Immunology. 20:1016-1026
Antimicrobials administered postexposure can reduce the incidence or progression of anthrax disease, but they do not protect against the disease resulting from the germination of spores that may remain in the body after cessation of the antimicrobial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0386884415d44b9f14b426dc105f80c5
https://doi.org/10.1128/cvi.00099-13
https://doi.org/10.1128/cvi.00099-13
Autor:
Gregory V. Stark, Crystal M. Briscoe, Emily S Syar, Sukjoon Park, Kevin P. Tordoff, Roy E. Barnewall, Daniel C. Sanford, Laurence Lemiale-Biérinx, Jamie L. Austin, Mario H. Skiadopoulos, Boris Ionin, Michael S. Anderson, Vladimir Savransky
Publikováno v:
Infection and Immunity. 81:1152-1163
Nonhuman primates (NHPs) and rabbits are the animal models most commonly used to evaluate the efficacy of medical countermeasures against anthrax in support of licensure under the FDA's “Animal Rule.” However, a need for an alternative animal mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23af769619a4e35a259c9674f369920
https://doi.org/10.1128/iai.01289-12
https://doi.org/10.1128/iai.01289-12